Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Return on Equity (2021 - 2025)

Historic Return on Equity for GeneDx Holdings (WGS) over the last 5 years, with Q3 2025 value amounting to 0.01%.

  • GeneDx Holdings' Return on Equity rose 4300.0% to 0.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01%, marking a year-over-year increase of 4300.0%. This contributed to the annual value of 0.22% for FY2024, which is 5100.0% up from last year.
  • Latest data reveals that GeneDx Holdings reported Return on Equity of 0.01% as of Q3 2025, which was up 4300.0% from 0.01% recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Return on Equity registered a high of 2.79% during Q3 2021, and its lowest value of 1.83% during Q1 2023.
  • For the 5-year period, GeneDx Holdings' Return on Equity averaged around 0.36%, with its median value being 0.42% (2024).
  • Its Return on Equity has fluctuated over the past 5 years, first plummeted by -32600bps in 2022, then skyrocketed by 12500bps in 2024.
  • Over the past 5 years, GeneDx Holdings' Return on Equity (Quarter) stood at 0.63% in 2021, then tumbled by -114bps to 1.35% in 2022, then skyrocketed by 46bps to 0.73% in 2023, then skyrocketed by 68bps to 0.23% in 2024, then soared by 103bps to 0.01% in 2025.
  • Its Return on Equity was 0.01% in Q3 2025, compared to 0.01% in Q2 2025 and 0.15% in Q1 2025.